Exciting Times in the World of Proteomics!
Thermo Fisher Scientific’s remarkable $3.1 billion acquisition of Olink Proteomics is a testament to the incredible technology that forms the foundation of Olink Proteomics. Olink’s advancements in proteomics have significant impacts on both ongoing drug discovery and future precision medicine.
Navinci and Olink Proteomics share the same ancestry, starting as a university spin-out from Ulf Landegren’s lab at Uppsala University and the invention of the Naveni® Proximit yLigation Assay. While Olink Proteomics has developed the PEA technology and with great knowledge and persistence, accelerating the entire field of proteomics, we’ve continued to build upon the same technological base of Proximity Ligation Assay.
Our focus at Navinci has been on developing Naveni Technology for in situ protein analysis in a spatial biology context, shedding light on protein function in spatial proteomics. As former members of the Olink family, we’re delighted to witness the remarkable success of Olink Proteomics, big congratulations to the whole team, that we know has worked very hard to make this happen!
Our journey continues in the realm of illuminating function in spatial proteomics, and we’re eager to contribute to this dynamic field. Stay tuned for our upcoming developments!
Read more in the article Thermo Fisher to Acquire Olink for $3.1B, Expanding Proteomics Presence.
Read more about Ulf Landegren’s innovations here.
Read more about Proximity Ligation Assay here.